Why the study?
Does candoxatril alter circulating levels of vasoactive peptides in patients with chronic heart failure?
Does candoxatril alter circulating levels of vasoactive peptides in patients with chronic heart failure?
Neutral endopeptidase inhibition with candoxatril increases circulating plasma levels of endothelin and CGRP in addition to natriuretic peptides in heart failure patients.
Answers are grounded in this paper and cite their sources.
Candoxatril raises ET, CGRP, and ANP in chronic HF; extends NEP inhibition effects beyond natriuretic peptides to vasoconstrictors and sensory neuropeptides.
AIMS: Candoxatril is a specific neutral endopeptidase (NEP) 24.11 inhibitor, and previous work has documented the effect of NEP inhibition on atrial and brain natriuretic peptides (ANP, BNP). The aim of the present study was to ascertain the effect of NEP inhibition on circulating levels of vasoactive peptides. METHODS: We studied seven patients with chronic heart failure who were randomized to receive candoxatril, candoxatril/captopril, captopril and placebo in a four way cross over, double-blind pattern. RESULTS: The mean circulating level of endothelin (ET) was increased 2 h after placebo (10 to 20 pg ml-1) and also calcitonin gene-related peptide (CGRP) (27 to 51 pg ml-1), but ANP levels changed little during this time (73 to 75 pg ml-1). Following candoxatril, however, ET (10 to 39 pg ml-1, P < 0.05), CGRP (34 to 99 pg ml-1, P < 0.05) and ANP (72 to 108 pg ml-1, P < 0.05) increased further. A similar result was observed following combined treatment with candoxatril and captopril. CONCLUSIONS: We conclude that neutral endopeptidase inhibition increases circulating plasma levels of ET and CGRP in addition to the natriuretic peptides.
No takes yet. Share an insight, caveat, or question.
McDowell et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: